Home/Pipeline/SKI-G-801

SKI-G-801

Acute Myeloid Leukemia (AML)

Phase not specifiedActive

Key Facts

Indication

Acute Myeloid Leukemia (AML)

Phase

Phase not specified

Status

Active

Company

Genosco

About Genosco

Genosco is a U.S.-based, clinical-stage biotech founded in 2018 with a core focus on kinase-targeted therapies. The company's differentiation lies in its proprietary discovery platform, GENO-K™/GENO-D™, designed to identify rare kinase sequences and develop selective inhibitors and protein degraders. Its pipeline includes both internally discovered assets and partnered programs, with lead candidates like a ROCK2 inhibitor entering Phase 1 and a legacy asset, lazertinib, already approved in combination therapies. The company appears to be a subsidiary of Oscotec Inc. and operates with a mix of independent R&D and strategic partnerships.

View full company profile

Therapeutic Areas

Oncology Fibrotic Diseases Hematology

Other Acute Myeloid Leukemia (AML) Drugs

Drug	Company	Phase	Status
Mipletamig (APVO436)	Aptevo Therapeutics	Phase 1/2	Active
lomonitinib	Lomond Therapeutics	IND-Enabling	Active
lonitoclax	Lomond Therapeutics	Phase 1	Active
Menin Inhibitor	Lomond Therapeutics	Discovery	Active
AB8939	AB Science	Phase 1	Active
Small-Molecule Therapeutic	AIkido Labs	Pre-clinical	Active
ADI-PEG 20 (pegargiminase)	Polaris Pharma	Phase 1	Active
NC525	NextCure	Preclinical	Active
ACD-101	Advanced Cellular Dynamics	Phase 1	IND-Enabling
ABD-3001	Advanced Biodesign	Phase 1	Active (trial began early 2023)
HC-7366	HiberCell	Phase 1b	Active - Monotherapy & in combination with venetoclax and azacitidine
Prexigebersen (BP1001)	Bio-Path Holdings	Phase 2	Active